» Articles » PMID: 35876890

APE1 Controls DICER1 Expression in NSCLC Through MiR-33a and MiR-130b

Overview
Publisher Springer
Specialty Biology
Date 2022 Jul 25
PMID 35876890
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidence suggests different, not completely understood roles of microRNA biogenesis in the development and progression of lung cancer. The overexpression of the DNA repair protein apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) is an important cause of poor chemotherapeutic response in lung cancer and its involvement in onco-miRNAs biogenesis has been recently described. Whether APE1 regulates miRNAs acting as prognostic biomarkers of lung cancer has not been investigated, yet. In this study, we analyzed miRNAs differential expression upon APE1 depletion in the A549 lung cancer cell line using high-throughput methods. We defined a signature of 13 miRNAs that strongly correlate with APE1 expression in human lung cancer: miR-1246, miR-4488, miR-24, miR-183, miR-660, miR-130b, miR-543, miR-200c, miR-376c, miR-218, miR-146a, miR-92b and miR-33a. Functional enrichment analysis of this signature revealed its biological relevance in cancer cell proliferation and survival. We validated DICER1 as a direct functional target of the APE1-regulated miRNA-33a-5p and miR-130b-3p. Importantly, IHC analyses of different human tumors confirmed a negative correlation existing between APE1 and Dicer1 protein levels. DICER1 downregulation represents a prognostic marker of cancer development but the mechanisms at the basis of this phenomenon are still completely unknown. Our findings, suggesting that APE1 modulates DICER1 expression via miR-33a and miR-130b, reveal new mechanistic insights on DICER1 regulation, which are of relevance in lung cancer chemoresistance and cancer invasiveness.

Citing Articles

Apurinic/Apyrimidinic Endodeoxyribonuclease 1 modulates RNA G-quadruplex folding of miR-92b and controls its expression in cancer cells.

Bellina A, Malfatti M, Salgado G, Fleming A, Antoniali G, Othman Z Proc Natl Acad Sci U S A. 2024; 121(46):e2317861121.

PMID: 39495925 PMC: 11572961. DOI: 10.1073/pnas.2317861121.


Emerging roles of bases modifications and DNA repair proteins in onco-miRNA processing: novel insights in cancer biology.

Mangiapane G, DAgostino V, Tell G Cancer Gene Ther. 2024; 31(12):1765-1772.

PMID: 39322751 DOI: 10.1038/s41417-024-00836-x.


Role of APE1 in hepatocellular carcinoma and its prospects as a target in clinical settings (Review).

Yang L, Sun Z Mol Clin Oncol. 2024; 21(5):82.

PMID: 39301126 PMC: 11411593. DOI: 10.3892/mco.2024.2780.


HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.

Liu J, Wang W, Wang K, Liu W, Zhao Y, Han X J Transl Med. 2024; 22(1):793.

PMID: 39198847 PMC: 11350990. DOI: 10.1186/s12967-024-05563-3.


Inhibition of non-small cell lung cancer metastasis by knocking down APE1 through regulating myeloid-derived suppressor cells-induced immune disorders.

Zhang Z, Lin Y, Pan X, Chen S Aging (Albany NY). 2024; 16(12):10435-10445.

PMID: 38885059 PMC: 11236315. DOI: 10.18632/aging.205938.


References
1.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

2.
Jeong J, Kim N, Pyo J . Prognostic roles of lymph node micrometastasis in non-small cell lung cancer. Pathol Res Pract. 2017; 214(2):240-244. DOI: 10.1016/j.prp.2017.11.005. View

3.
Drusco A, Croce C . MicroRNAs and Cancer: A Long Story for Short RNAs. Adv Cancer Res. 2017; 135:1-24. DOI: 10.1016/bs.acr.2017.06.005. View

4.
Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

5.
Hwang H, Mendell J . MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006; 94(6):776-80. PMC: 2361377. DOI: 10.1038/sj.bjc.6603023. View